Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial
- 18 April 2017
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 34 (5) , 96
Abstract
The LUMIRA trial evaluated the effectiveness of radiofrequency (RFA) and microwave ablation (MWA) in lung tumours ablation and defining more precisely their fields of application. It is a controlled prospective multi-centre random trial with 1:1 randomization. Fifty-two patients in stage IV disease (15 females and 37 males, mean age 69 y.o., range 40–87) were included. We randomized the patients in two different subgroups: MWA group and RFA group. For each group, we evaluated the technical and clinical success, the overall survival and complication rate. Inter-group difference was compared using Chi-square test or Fisher’s exact test for categorical variables and one-way ANOVA test for continuous variables. For RFA group, there was a significant reduction in tumour size only between 6 and 12 months (p value = 0.0014). For MWA group, there was a significant reduction in tumour size between 6 and 12 months (p value = 0.0003) and between pre-therapy and 12 months (p value = 0.0215). There were not significant differences between the two groups in terms of survival time (p value = 0.883), while the pain level in MWA group was significantly less than in RFA group (1.79 < 3.25, p value = 0.0043). In conclusion, our trial confirms RFA and MWA are both excellent choices in terms of efficacy and safety in lung tumour treatments. However, when compared to RFA therapy, MWA produced a less intraprocedural pain and a significant reduction in tumour mass.Keywords
This publication has 53 references indexed in Scilit:
- Lung Tumor Radiofrequency Ablation: Where Do We Stand?CardioVascular and Interventional Radiology, 2010
- Race and Sex Differences in the Receipt of Timely and Appropriate Lung Cancer TreatmentMedical Care, 2009
- Radiofrequency and Microwave Ablation of the Liver, Lung, Kidney, and Bone: What Are the Differences?Current Problems in Diagnostic Radiology, 2009
- Tumour ablation: current role in the liver, kidney, lung and boneCancer Imaging, 2008
- Radiofrequency ablation of pulmonary tumours: current statusCancer Imaging, 2008
- Post‐radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: One centre experience and review of published worksAustralasian Radiology, 2007
- Minimally invasive treatment for liver and lung metastases in colorectal cancerBMJ, 2007
- Characterization of the RF ablation-induced ‘oven effect’: The importance of background tissue thermal conductivity on tissue heatingInternational Journal of Hyperthermia, 2006
- Percutaneous ablation of hepatocellular carcinoma: State-of-the-artLiver Transplantation, 2004
- A critical review of visual analogue scales in the measurement of clinical phenomenaResearch in Nursing & Health, 1990